Anthera Pharmaceuticals, Inc.
ANTH
Rank in Stocks
#34933
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on... Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
Share Price
$0.0001
Last synced: 2026-11-06
Market Cap
$2.62K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Anthera Pharmaceuticals, Inc. (ANTH)
Category
Healthcare
EPS for Anthera Pharmaceuticals, Inc. (ANTH)
EPS as of March 2018 TTM: $-0.47
According to Anthera Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-0.47. At the end of 2017 the company had an EPS of $-1.65, an increase over its 2016 EPS of $-10.38.
EPS history for Anthera Pharmaceuticals, Inc. from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.47 | -71.52% |
| 2017 | $-1.65 | -84.10% |
| 2016 | $-10.38 | 32.40% |
| 2015 | $-7.84 | -29.56% |
| 2014 | $-11.13 | -23.24% |
| 2013 | $-14.50 | -77.95% |
| 2012 | $-65.77 | -59.67% |
| 2011 | $-163.06 | 44.43% |
| 2010 | $-112.90 | -78.12% |
| 2009 | $-516.03 | -32.57% |
| 2008 | $-765.33 | -29.56% |
| 2007 | $-1.09K | 25.17% |
| 2006 | $-868.00 | 1,507.41% |
| 2005 | $-54.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,431.91% |
US
|
|
| $-7.07 | 1,404.26% |
US
|
|
| $-5.29 | 1,025.53% |
AU
|
|
| $12.88 | -2,840.45% |
BE
|
|
| $21.56 | -4,687.23% |
NL
|
Questions about Anthera Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Anthera Pharmaceuticals, Inc.'s earnings per share (EPS)?
Anthera Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-0.47, as of Mar 2018.
What was Anthera Pharmaceuticals, Inc.'s earnings per share (EPS) in 2017?
In 2017, Anthera Pharmaceuticals, Inc.'s earnings per share (EPS) was $-1.65, compared with $-10.38 in 2016.
How has Anthera Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2012?
From 2012 to 2017, Anthera Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2017 ($-1.65) and lowest in 2012 ($-65.77).
How does Anthera Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Anthera Pharmaceuticals, Inc.'s earnings per share (EPS) ($-0.47) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.